Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis
Open Access
- 5 November 2024
- journal article
- research article
- Published by Elsevier in The Lancet Planetary Health
- Vol. 8 (11) , e915-e923
Abstract
No abstract availableKeywords
Funding Information
- Erasmus Medisch Centrum
- Erasmus MC Kanker Instituut
This publication has 27 references indexed in Scilit:
- Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic societyESMO Open, 2024
- Model‐Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid TumorsClinical Pharmacology & Therapeutics, 2024
- Circular material flow in the intensive care unit—environmental effects and identification of hotspotsIntensive Care Medicine, 2022
- Streamlined life cycle assessment of single use technologies in biopharmaceutical manufactureNew Biotechnology, 2022
- Environmental footprint of regular and intensive inpatient care in a large US hospitalThe International Journal of Life Cycle Assessment, 2021
- Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19JAMA Oncology, 2020
- Introduction of a process mass intensity metric for biologicsNew Biotechnology, 2019
- Environmental sustainability assessment of the manufacturing process of a biological active pharmaceutical ingredientJournal of Chemical Technology & Biotechnology, 2019
- The ecoinvent database version 3 (part I): overview and methodologyThe International Journal of Life Cycle Assessment, 2016
- An environmental life cycle assessment comparison of single-use and conventional process technology for the production of monoclonal antibodiesJournal of Cleaner Production, 2013